Suppr超能文献

急性肺栓塞的管理

Management of Acute Pulmonary Embolism.

作者信息

Tice Connor, Seigerman Matthew, Fiorilli Paul, Pugliese Steven C, Khandhar Sameer, Giri Jay, Kobayashi Taisei

机构信息

Department of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA 19104 USA.

Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, 3400 Civic Center Blvd, Philadelphia, PA 19104 USA.

出版信息

Curr Cardiovasc Risk Rep. 2020;14(12):24. doi: 10.1007/s12170-020-00659-z. Epub 2020 Oct 6.

Abstract

PURPOSE OF THE REVIEW

Over 100,000 cardiovascular-related deaths annually are caused by acute pulmonary embolism (PE). While anticoagulation has historically been the foundation for treatment of PE, this review highlights the recent rapid expansion in the interventional strategies for this condition.

RECENT FINDINGS

At the time of diagnosis, appropriate risk stratification helps to accurately identify patients who may be candidates for advanced therapeutic interventions. While systemic thrombolytics (ST) is the mostly commonly utilized intervention for high-risk PE, the risk profile of ST for intermediate-risk PE limits its use. Assessment of an individualized patient risk profile, often via a multidisciplinary pulmonary response team (PERT) model, there are various interventional strategies to consider for PE management. Novel therapeutic options include catheter-directed thrombolysis, catheter-based embolectomy, or mechanical circulatory support for certain high-risk PE patients. Current data has established safety and efficacy for catheter-based treatment of PE based on surrogate outcome measures. However, there is limited long-term data or prospective comparisons between treatment modalities and ST. While PE diagnosis has improved with modern cross-sectional imaging, there is interest in improved diagnostic models for PE that incorporate artificial intelligence and machine learning techniques.

SUMMARY

In patients with acute pulmonary embolism, after appropriate risk stratification, some intermediate and high-risk patients should be considered for interventional-based treatment for PE.

摘要

综述目的

每年超过10万例心血管相关死亡由急性肺栓塞(PE)所致。虽然抗凝治疗一直是PE治疗的基础,但本综述强调了该病症介入治疗策略最近的迅速扩展。

最新发现

在诊断时,适当的风险分层有助于准确识别可能适合进行高级治疗干预的患者。虽然全身溶栓(ST)是高危PE最常用的干预措施,但ST用于中危PE的风险状况限制了其应用。通过多学科肺反应团队(PERT)模型等方式评估个体患者风险状况后,对于PE管理有多种介入策略可供考虑。新的治疗选择包括导管定向溶栓、基于导管的栓子切除术,或为某些高危PE患者提供机械循环支持。目前的数据已基于替代结局指标确立了基于导管治疗PE的安全性和有效性。然而,长期数据有限,且治疗方式与ST之间的前瞻性比较也较少。虽然现代横断面成像改善了PE诊断,但人们对结合人工智能和机器学习技术的PE诊断模型改进也很感兴趣。

总结

在急性肺栓塞患者中,经过适当的风险分层后,一些中高危患者应考虑接受基于介入的PE治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2ff7/7538277/9fcce7d32f14/12170_2020_659_Fig1_HTML.jpg

相似文献

1
Management of Acute Pulmonary Embolism.
Curr Cardiovasc Risk Rep. 2020;14(12):24. doi: 10.1007/s12170-020-00659-z. Epub 2020 Oct 6.
2
Interventional Therapies for Acute Pulmonary Embolism.
Surg Clin North Am. 2022 Jun;102(3):429-447. doi: 10.1016/j.suc.2022.02.004. Epub 2022 Apr 21.
3
Interventional Treatment of Pulmonary Embolism.
Circ Cardiovasc Interv. 2017 Feb;10(2). doi: 10.1161/CIRCINTERVENTIONS.116.004345.
4
The implementation of a pulmonary embolism response team in the management of intermediate- or high-risk pulmonary embolism.
J Vasc Surg Venous Lymphat Disord. 2019 Jul;7(4):493-500. doi: 10.1016/j.jvsv.2018.11.014. Epub 2019 Mar 29.
5
Interventional Therapies in Acute Pulmonary Embolism.
Interv Cardiol Clin. 2020 Apr;9(2):229-241. doi: 10.1016/j.iccl.2019.12.003. Epub 2020 Feb 10.
7
Diagnosis and management of life-threatening pulmonary embolism.
J Intensive Care Med. 2011 Sep-Oct;26(5):275-94. doi: 10.1177/0885066610392658. Epub 2011 May 23.
10
Pharmacological and interventional management of pulmonary embolism: where do we stand?
Future Cardiol. 2022 Mar;18(3):191-206. doi: 10.2217/fca-2021-0109. Epub 2022 Feb 8.

引用本文的文献

1
National Trends in Pulmonary Embolism Visit in United State Emergency Departments and Associated Costs (2006-2018).
Emerg Med Int. 2025 Jan 20;2025:6610196. doi: 10.1155/emmi/6610196. eCollection 2025.
2
3
Decoding Pulmonary Embolism: Pathophysiology, Diagnosis, and Treatment.
Biomedicines. 2024 Aug 23;12(9):1936. doi: 10.3390/biomedicines12091936.
4
Multidisciplinary Approach to Pulmonary Embolism and the Role of the Pulmonary Embolism Response Team.
Curr Cardiol Rep. 2024 Aug;26(8):843-849. doi: 10.1007/s11886-024-02084-9. Epub 2024 Jul 4.
5
Comparison of Treatment Approaches and Subsequent Outcomes within a Pulmonary Embolism Response Team Registry.
Crit Care Res Pract. 2024 Mar 22;2024:5590805. doi: 10.1155/2024/5590805. eCollection 2024.
8
A Case of Pulmonary Infarction Resembling Pneumonia during Immunosuppressive Treatment for Rheumatoid Arthritis.
Case Rep Rheumatol. 2021 Aug 18;2021:5983580. doi: 10.1155/2021/5983580. eCollection 2021.

本文引用的文献

1
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2020 Jun 16;75(23):2950-2973. doi: 10.1016/j.jacc.2020.04.031. Epub 2020 Apr 17.
2
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
3
Evaluation of acute pulmonary embolism and clot burden on CTPA with deep learning.
Eur Radiol. 2020 Jun;30(6):3567-3575. doi: 10.1007/s00330-020-06699-8. Epub 2020 Feb 16.
7
Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium.
Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619853037. doi: 10.1177/1076029619853037.
10
Ultrasound-assisted catheter-directed thrombolysis compared with anticoagulation alone for treatment of intermediate-risk pulmonary embolism.
Pulm Circ. 2018 Oct-Dec;8(4):2045894018800265. doi: 10.1177/2045894018800265. Epub 2018 Aug 24.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验